A detailed history of Jane Street Group, LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 49,558 shares of PYXS stock, worth $83,753. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,558
Previous 35,209 40.75%
Holding current value
$83,753
Previous $116,000 56.03%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.83 - $3.94 $40,607 - $56,535
14,349 Added 40.75%
49,558 $181,000
Q2 2024

Aug 14, 2024

SELL
$3.06 - $5.58 $428,531 - $781,439
-140,043 Reduced 79.91%
35,209 $116,000
Q1 2024

May 15, 2024

BUY
$2.03 - $6.59 $325,279 - $1.06 Million
160,236 Added 1067.1%
175,252 $746,000
Q4 2023

Feb 14, 2024

BUY
$1.4 - $2.09 $21,022 - $31,383
15,016 New
15,016 $27,000
Q1 2023

May 15, 2023

BUY
$1.38 - $6.0 $104,093 - $452,580
75,430 New
75,430 $302,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $59.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.